Last reviewed · How we verify
Rabbit ATG, (Genzyme)
Rabbit ATG is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering complement-mediated and antibody-dependent cellular cytotoxicity.
Rabbit ATG is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering complement-mediated and antibody-dependent cellular cytotoxicity. Used for Prevention of acute organ rejection in renal transplantation, Treatment of acute rejection episodes in transplant recipients, Aplastic anemia.
At a glance
| Generic name | Rabbit ATG, (Genzyme) |
|---|---|
| Also known as | Thymoglobuline, Anti-thymoeyteGlobulin |
| Sponsor | Jinan Military General Hospital |
| Drug class | Polyclonal antithymocyte globulin (ATG) |
| Target | T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Rabbit ATG is derived from immunized rabbits and contains polyclonal antibodies against human T-cell antigens. It binds to circulating and tissue-resident T cells, leading to their elimination through complement activation and antibody-dependent cell-mediated cytotoxicity. This profound immunosuppression is used to prevent graft rejection and treat T-cell mediated conditions.
Approved indications
- Prevention of acute organ rejection in renal transplantation
- Treatment of acute rejection episodes in transplant recipients
- Aplastic anemia
Common side effects
- Fever
- Chills
- Thrombocytopenia
- Leukopenia
- Serum sickness
- Infection
- Rash
Key clinical trials
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
- 1 vs 7 RATG Infusions in Renal Transplantation
- ATG Plus Low-dose PT-Cy for GVHD Prevention (PHASE3)
- Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease (PHASE1)
- Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome (PHASE2)
- Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia (PHASE2)
- The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rabbit ATG, (Genzyme) CI brief — competitive landscape report
- Rabbit ATG, (Genzyme) updates RSS · CI watch RSS
- Jinan Military General Hospital portfolio CI